Veracyte VCYT is well positioned for growth in the coming quarters, driven by continued sales momentum for its Afirma and Decipher Prostate tests. However, macroeconomic pressures and intense competition remain key concerns.
In the past year, this Zacks Rank #1 (Strong Buy) stock has risen 51.5% against the industry’s 3.4% decline. The S&P 500 composite has gained 20.5% in the same time frame.
The renowned diagnostics company has a market capitalization of $3.53 billion. The company’s earnings yield of 5.6% favorably compares to the industry’s -1% yield. Veracyte topped earnings estimates in each of the trailing four quarters, the average surprise being 45.9%.
Positives for VCYT Stock
Afirma Continues to Outperform: Veracyte’s comprehensive Afirma solution, which includes the Afirma GSC and Afirma Xpression Atlas, addresses the complexities of thyroid nodule diagnosis and is designed to deliver actionable results from a single fine-needle aspiration biopsy. Adoption has remained broad, with Afirma volume rising 10% to about 18,600 tests in the second quarter. Second-quarter 2026 revenues increased 18%, supported by higher utilization, share gains and better reimbursement.
The V2 transcriptome workflow continued to lower the no-result rate, contributing about 400 basis points to second-quarter volume growth by converting more low-input RNA samples into reportable results. The company now expects Afirma revenues to rise approximately 12% to 14% in 2026. Continued evidence generation, including 10 conference abstracts in the second quarter, supports the franchise’s ability to sustain adoption.
Strength of the Decipher Franchise: Decipher Prostate uses whole-transcriptome analysis and machine learning to help predict metastatic risk and guide treatment decisions across prostate cancer settings. In the second quarter of 2026, Decipher revenues increased 20% year over year to $91.9 million and volume rose 17% to approximately 29,700 tests. Orders per physician reached a record high, alongside an increase in the number of new ordering physicians.
Evidence generation remains central to the longer-term case. Decipher appeared in more than 35 publications and abstracts in the second quarter, including predictive evidence from the ENZAMET trial in metastatic prostate cancer. Additional studies in low-risk and active-surveillance populations are expected to begin reading out in 2027, creating a pathway to broaden clinical support over time.
What Ails VCYT Stock?
Competitive Landscape: Veracyte operates in markets where genomic diagnostics adoption is advancing and competitors continue to invest in alternative technologies and broader test menus. In thyroid testing, competitors include companies and academic institutions using next-generation sequencing or targeted mutation panels.
Intense competition may require continued investment in clinical evidence and commercialization to sustain adoption. Intellectual property disputes add another layer of execution risk. Veracyte’s patent case against Sonic Healthcare USA remains active, with a jury trial scheduled for the first quarter of 2027 after the court denied Sonic’s motion to dismiss and one asserted patent entered ex parte reexamination.
Image Source: Zacks Investment Research
Macro Issues Hurt Growth: Veracyte remains exposed to inflation, interest-rate volatility, foreign exchange movements, evolving trade policies and tariffs that can affect operating costs, payer behavior and testing demand. Geopolitical developments can also disrupt operations, including conditions in and around Israel, where the company has activities in Haifa. These risks come as Veracyte increases investment to support its core portfolio and new product launches.
In the second quarter of 2026, non-GAAP sales and marketing expense rose to $25.5 million from $23.1 million a year earlier, while non-GAAP R&D increased to $26.3 million from $14.3 million, reflecting both organizational changes and higher clinical and product investment. Continued cost discipline will be needed as these programs scale.
VCYT Stock Estimate Trend
In the past 30 days, the Zacks Consensus Estimate for 2026 earnings per share (EPS) has increased 4.3% to $1.93.
The Zacks Consensus Estimate for the company’s 2026 revenues is pegged at $591.5 million, implying a 14.4% rise from the year-ago reported number.
Other Key Picks
Some other top-ranked stocks in the broader medical space are Globus Medical GMED, Envista NVST and Teleflex TFX.
Globus Medical has an earnings yield of 5.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED’s shares have rallied 42.3% against the industry’s 6.3% decline over the past year.
GMED sports a Zacks Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Envista, carrying a Zacks Rank #2 (Buy) at present, has an earnings yield of 5.6% compared with the industry’s 2.6% yield. Shares of the company have risen 38% against the industry’s 6.3% decline. NVST’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 19.4%.
Teleflex, carrying a Zacks Rank #2 at present, has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 12.8% growth. Its earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. TFX’s shares have rallied 5% against the industry’s 6.2% decline over the past year.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Veracyte, Inc. (VCYT): Free Stock Analysis Report
Teleflex Incorporated (TFX): Free Stock Analysis Report
Globus Medical, Inc. (GMED): Free Stock Analysis Report
Envista Holdings Corporation (NVST): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).